Here are the Form 4 insider transactions from Kyntra Bio, Inc. (KYNB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KYNB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYNB filings page.
Kyntra Bio, Inc. (KYNB) director Andrew E. Singer was granted 14,000 stock options on October 1, 2026, covering 14,000 shares of common stock. The options have a $6.50 per-share exercise price, vest in twelve equal quarterly installments measured from the grant date, and expire September 30, 2036.
KYNTRA BIO, INC. (KYNB) reported that CEO and director Thane Wettig26,796 shares directly and 40 shares indirectly through his spouse. No transactions were reported under a Rule 10b5-1 trading plan.
KYNTRA BIO, INC. (KYNB) reported that Chief Financial Officer David DeLucia had 22 shares of common stock disposed of on September 6, 2026 as part of a tax-withholding disposition related to vesting restricted stock units. The shares were withheld by the issuer to satisfy a tax obligation, not sold in an open-market trade. Following this event, DeLucia holds 4,355 shares of KYNTRA BIO common stock directly, and no Rule 10b5-1 trading plan is reported for this transaction.
KYNTRA BIO, INC. director Ho Maykin received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036. They vest in four equal quarterly installments from the grant date, and this filing shows 7,000 options held directly after the award.
Kyntra Bio director Jeffrey L. Edwards received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and were granted as a compensation award rather than a market purchase or sale.
The award vests in four equal quarterly installments measured from the grant date and expires on June 11, 2036. Following this grant, Edwards holds options for 7,000 shares directly, giving him equity-based incentive aligned with the company’s future performance.
KYNTRA BIO, INC. director Michael Kauffman received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036. These options vest in four equal quarterly installments from the grant date, and his reported option holdings following this grant total 7,000 derivative securities.
KYNTRA BIO, INC. director James A. Schoeneck received a grant of stock options covering 7,000 shares of common stock. The options have an exercise price of $7.13 per share and expire on June 11, 2036.
The 7,000 options vest in four equal quarterly installments starting from the grant date. Following this award, Schoeneck holds 7,000 derivative securities directly in the form of these stock options.
KYNTRA BIO, INC. CEO Thane Wettig reported routine share updates in a Form 4. The filing shows 198 shares of common stock were disposed of to cover a tax obligation at $6.71 per share when restricted stock units vested, a non‑market transaction. After this withholding, he directly holds 27,005 common shares and has an additional 40 shares reported as indirectly owned through his spouse.
KYNTRA BIO, INC. Chief Financial Officer David DeLucia reported a routine tax-related share disposition tied to equity compensation. On the reported date, 52 shares of common stock were withheld by the company at a value of $6.71 per share to satisfy a tax obligation that arose when restricted stock units vested. Following this withholding, DeLucia holds 4,377 shares of KYNTRA BIO common stock directly.
KYNTRA BIO, INC. CEO and director Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, increasing his direct holdings to 27,203 shares. A separate line shows 40 shares of common stock held indirectly through his spouse.
KYNTRA BIO, INC. CEO Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, bringing his direct holdings to 27,203 shares. He also reports indirect ownership of 40 shares held by his spouse.
Kyntra Bio, Inc. reported that CEO and director Thane Wettig received a grant of stock options. On February 3, 2026, he was awarded options to purchase 60,000 shares of common stock at an exercise price of $8.50 per share, with no cash price paid for the grant itself.
The options vest in equal amounts quarterly over four years starting from February 3, 2026, and are exercisable until February 2, 2036. Following this award, Wettig beneficially owns 60,000 stock options, held directly.
Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.
The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.